CASE REPORT article
Front. Oncol.
Sec. Gastrointestinal Cancers: Gastric and Esophageal Cancers
Case report: A Successfully Managed Case of SMARCA4-Deficient Undifferentiated Gastric Carcinoma
Provisionally accepted
- Jiangsu Cancer Hospital, Nanjing Medical University, Nanjing, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
We report a case of SMARCA4-deficient poorly-to-undifferentiated gastric carcinoma. The patient underwent surgical resection. Postoperative treatment combined chemotherapy, immunotherapy, and targeted therapy. The regimen included ifosfamide, liposomal doxorubicin hydrochloride, cadonilimab, and anlotinib capsules. Follow-up to date shows no tumor recurrence or metastasis. The postoperative relapse-free survival (RFS) has now reached 33 months. Primary gastric SMARCA4-deficient undifferentiated tumors carry a poor prognosis, with survival typically under one year. Here we present a successfully treated case of this tumor type originating in the stomach. This case may serve as a reference for future management of such tumors.
Keywords: BRG1, Immunotherapy, SMARCA4, targeted therapy, Undifferentiated gastric carcinoma
Received: 02 Jan 2026; Accepted: 09 Feb 2026.
Copyright: © 2026 Peng, Shi, Wu, Chen and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Gang Li
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.